NEW YORK – Lumea and Caris Life Sciences said on Thursday that they have agreed to make Caris' sequencing-based urology tools available through Lumea's BxLink digital pathology platform.
Under the terms of the deal, Lumea's customers will be able to order through BxLink Caris' molecular profiling services that are used to aid the diagnosis and treatment of urological cancers as well as track their order progress and access test results. The deal includes the integration into the platform of Irving, Texas-based Caris's comprehensive whole-exome and whole-transcriptome sequencing tests.
Lehi, Utah-based Lumea said that the partnership will help urologists make informed decisions more quickly and efficiently through the platform that they use to manage patient care. Caris President David Spetzler said in a statement that the integration of Caris' tests into BxLink will help to make precision healthcare accessible to more physicians and patients.
"Delivering critical molecular results directly at the point of care is paramount to empowering urologists to make timely and informed decisions, ultimately improving patient outcomes in the battle against urological cancers," he said.
Caris said earlier this month that it had secured US Food and Drug Administration approval for its MI Cancer Seek next-generation sequencing-based assay as a companion diagnostic for various targeted therapies.